OACCW · Oaktree Acquisition Corp. III Life Sciences
Substantial doubt about the company's ability to continue as a going concern.
“Such potential liquidity shortfalls and mandatory liquidation condition raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Price & Indicators
The closing range uses available history since Jul 24, 2026; less than a full year is stored.
Up next
Technicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OACCW
this stock
Oaktree Acquisition Corp. III Life Sciences
|
$262.05M | — | — | — | — |
|
VYLR
Vylor Inc.
|
$48.80B | — | — | — | — |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$648.78M | +2.9% | — | — | 0.2% |
|
EVAC
EQV Ventures Acquisition Corp. II
|
$603.18M | +3.0% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 84.1%
- Net QoQ
- +42.3K sh
- Top holder
- AQR Arbitrage LLC
- Filed
- Oct 16, 2026
- This year
- 9
Oaktree Acquisition Corp. III Life Sciences postponed its shareholder General Meeting, originally set for October 16, 2026, to October 23, 2026 at 10:00 a.m. Eastern Time to permit further proxy solicitation for the initial business combination extension proposal.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OACCW | -7.7% | — | — | -9.5% | — |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -6.5% | — | — | -10.3% | — |